Hot Stocks: Brokerages view on Indian Hotels, Titan Company, Paytm and Dr Lal PathLabs

Goldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and the trend continues.

Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.